Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting

This study aims to evaluate the efficacy of antiviral prophylaxis in preventing in-hospital influenza transmission. We will enroll hospitalized patients with confirmed influenza (index cases) and their uninfected roommates (room contacts). These room contacts will be randomized in a 1:1:1 ratio to one of three prophylactic groups: placebo, suraxavir marboxil, or oseltamivir. The primary outcome will be the rate of influenza infection among the room contacts, which will be monitored to determine the effectiveness of the interventions.

NCT Number	NCT07236814
Lead Sponsor	Capital Medical University
Conditions	Influenza
Enrollment	384 participants
Start Date	2025-11-28
Primary Completion	2027-03-01 (estimated)
Study Completion	2027-03-06 (estimated)
Updated on ClinicalTrials.gov	2026-03-23